Dow Jones received a payment from EQS/DGAP to publish this press release.
Edison Investment Research Limited Edison initiates coverage on Actinogen Medical (ACW) 18-March-2019 / 12:33 GMT/BST London, UK, 18 March 2019 *Edison initiates coverage on Actinogen Medical (ACW)* Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem(R) is a selective 11ß-HSD1 inhibitor that is able to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in Alzheimer's disease (AD). The ongoing Phase II XanADu trial is fully enrolled with mild AD patients, who receive Xanamem in conjunction with standard of care. The results are due by end-Q219 and will shape further development of Xanamem. Our valuation is A$195m or A$0.17/share. We value Actinogen at A$195m or A$0.17/share (includes A$9.9m in cash at end-FY19. The company is well funded to reach the XanADu trial readout and prepare for further studies. Funding needs for late-stage R&D will depend on the scale of the next trials and the timing of any potential licensing deal. Our current scenario assumes that Xanamem is a cognitive enhancer that provides a beneficial addition to standard of care; however, this is to be confirmed by the XanADu trial results. Click here [1] to view the full report. Subscribe [2]to Edison's content to receive reports by email. All reports published by Edison are free-to-access and available on thewebsite [3]. *About Edison:* Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority [4]. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. *For more information please contact Edison:* Jonas Peciullis, +44 (0)20 3077 5728 Alice Nettleton, +44 (0)20 3077 5700 Dennis Hulme, +61 (0)28 249 8345 healthcare@edisongroup.com Learn more at Edisongroup.com [3] and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-group- [5] Twitter www.twitter.com/Edison_Inv_Res [6] YouTube www.youtube.com/edisonitv [7] Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. End of Announcement - EQS News Service 788593 18-March-2019 1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f8e6371aefdd6e4a4a87404f8ea976c8&application_id=788593&site_id=vwd&application_name=news 2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=dc4b6da9609a3fa15934b7007f0912b2&application_id=788593&site_id=vwd&application_name=news 3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=c0da504bc37f356d3fffdc8eee905ae7&application_id=788593&site_id=vwd&application_name=news 4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=105fe9be9b5e36892886e5a39d51d4b7&application_id=788593&site_id=vwd&application_name=news 5: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=afe662765000a80ab72afd922939c992&application_id=788593&site_id=vwd&application_name=news 6: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ec2d264fe4f303e2143a2e85c6eaa823&application_id=788593&site_id=vwd&application_name=news 7: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6b959e4d7ee3c402b931a274d2bbe945&application_id=788593&site_id=vwd&application_name=news
(END) Dow Jones Newswires
March 18, 2019 08:33 ET (12:33 GMT)
© 2019 Dow Jones News
